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a b s t r a c t
Complete removal of a meningioma (MG) does not guarantee relapse-free survival. Altera-
tions on several chromosomes responsible for MG recurrence were suggested, although their
role was not validated by a systematic review. Following the analysis of own 161 cases, all
previously published data has been collected for evidence synthesis. Based on own series,
WHO grade >I (odds ratio (OR) = 92.0; 95%CI: 19.1–443.5) and a combination of loss of
heterozygosity (LOH) on 1p and 14q (OR = 10.2; 95%CI: 19–55.7) were the independent
recurrence-speciﬁc prognosticators. The deleterious role of LOH on 1p/14q was demonstrat-
ed in a subset of parasagittal and falcine MGs. A total of 742 cases and 10 studies were pooled
for the Individual Patient Data and Aggregate Data models of meta-analysis, respectively.
The prognostic role of WHO classiﬁcation (OR = 90.4) and anomaly of chromosome 14
(OR = 3.5) was conﬁrmed. LOH on 14 showed lesser impact on recurrence than suggested
by the WHO grading (area under the curve 0.65 for LOH vs. 0.74 for WHO). Fixed effect model
of meta-analysis provided high summarized OR values for 1p (OR = 5.4; 95%CI: 3.6–8.1) and
14q (OR = 7.6; 95%CI: 4.3–13.6), and low for chromosome 22 (OR = 1.6; 95%CI: 1.1–2.4). Final
appraisal of recurrence-associated chromosomal alterations indicated that arms 1p and 14q
deserve attention while predicting MG recurrence.
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Meningiomas (MGs) are the most frequent intracranial
tumour, accounting for up to 30% of the neoplasms in that
location. Although most of them are slow-growing, solitary
and benign tumours, their aggressive biological behaviour has
been reported [1–3]. These tumours are regarded by experi-
enced surgeons as easy to manage, however their complete
removal is occasionally precluded due to the vicinity of vital
structures. Even after total resection, about 3–10% of MGs
relapse [4] and a less favourable prognosis is attributed to
younger age, malignant histology and unnoticed brain inva-
sion [1,5–8]. The World Health Organization (WHO) classiﬁca-
tion has facilitated estimating the prognosis [2,3,5,6,9]. In
addition to the WHO classiﬁcation, histopathological ﬁndings
such as Ki-67/MIB-1 labelling index and proliferating cell
nuclear antigen can independently predict the behaviour of a
MG [3,10].
The molecular basis of MG's malignant behaviour has been
recently scrutinized. A broad array of genetic alterations has
been suggested, including complete or partial chromosome
loss or gain, gene mutation and methylation [1–4,6,7,10–19].
Concerning the karyotype level, allelic loss of heterozygosity
(LOH) on chromosomes 1, 6, 10, 14, and 22 has been postulated
to increase the risk of malignant behaviour of sporadic MGs
[2,4,11–13,15,18,20,21]. Beyond the deleterious role of a single
anomaly, various conﬁgurations of LOH on several chromo-
somes were attributed to more aggressive phenotype of MG
[4,12]. Most studies associated molecular aberrations with
tumorigenesis, increased replication rate, histological pro-
gression or a higher WHO grade, occasionally focused on
tumour recurrence [4,11,16]. According to Lee, who collected
the largest cohort, the arm losses of 6q and 14q were the most
reliable indicators of the MG relapse [4]. The previously
published case series rarely exceeded 100 specimens, the
investigators evaluated non-replicated chromosomal altera-
tions and/or utilized completely different clinical endpoints.
As of yet, genetic exams in MGs have not been applied in
routine clinical practice. Moreover, dispersed molecular
ﬁndings were never summarized in a systematic review. For
these reasons, the molecular biology of MGs seems unjustly
underappreciated while the development of a recurrence-
speciﬁc genomic landscape seems feasible [16].
The aim of our study was to gather all the previous reports
of MG-speciﬁc chromosomal alterations in order to extract
reliable prognostic molecular biomarkers.
2. Material and methods
2.1. Study design
This study evaluated the impact of chromosomal alterations
in sporadic MGs on recurrence. Following the identiﬁcation of
chromosomal arm losses in the entire own series of MGs, the
individual features of tumour recurrence pooled including all
accessible data from the existing literature and using PRISMA
methodology. (For details – see 'Systematic Review methodol-
ogy' in the electronic supplementary materials.)2.2. Own series
The diagnosis of sporadic non NF1/NF2-related intracranial
MG was based on the contrast-enhanced computer tomogra-
phy (CT) or magnetic resonance imaging (MRI) of the head,
followed by histopathological examination. Following the
approval of the local Bioethics Committee a total of 136 MGs
of various intracranial locations were collected prospectively
since 2002. All consenting patients were managed operatively
at two neurosurgery departments (institution name deleted
for peer-review purposes), gross total resection was intended
in all of them. Basic demographics included patient age, sex
and MG location. The Simpson grading for the extent of the
tumour removal was utilized, though sparsely reported. The
resection rate was not analyzed because it did not adhere to
the RANO criteria for volumetric tumour remnant assessment
[22]. The majority of patients were followed-up (121 of 136;
89.0%), however the follow-up time was not standardized. As
the time to remote postoperative brain imaging was not
established in the protocol, both the follow-up and time to
recurrence were not valid for the statistical analysis. All
tumour specimens were classiﬁed as grade I, II or III according
to the World Health Organization (WHO) criteria, relevant to
the year of assessment [9,23]. (For details – see 'Loss of
heterozygosity analysis' in the electronic supplementary
materials.)
During the surgery for the MG recurrence, the tissues were
biopsied only for pathology and the genetic evaluation was
skipped. A subgroup of recurrent MGs of parasagittal and
falcine locations was selected throughout the entire group to
demonstrate the recurrence-associated chromosomal anom-
alies, such as the 1p/14q alteration.
2.3. Systematic review and meta-analysis




Our study group consisted of 161 patients, (104 females, 64.6%
and 57 males, 35.4%) diagnosed with MG. Their mean age was
56.1 (SD  14.5; min–max 22–92). The study group consisted of a
total of 161 patients harbouring meningiomas. 104 of our
patients were female (64.6%), and 57 were male (35.4%). 138 of
the resected tumours were WHO grade 1 (85.7%), 22 were grade 2
(13.7%) and only one was grade 3 (0.6%). Of the entire cohort, a
total of 35 meningiomas (21.7%) recurred during follow-up. (As
noted in Methods, the follow-up time was not measured nor
standardized.) As suspected, tumour recurrence strongly
depended on the WHO grade (p < 0.01), speciﬁcally; 10.1% grade
I (14 of 138), 90.9% grade II (20 of 22) and 100% (1 of 1) of grade III
tumours relapsed. Among the determined set of loci, the
recurrence rate was signiﬁcantly greater when chromosome
arms 1p (cytoband 1p33-32.3;), 14q (14q32.33) or 22q (22q11.23)
were affected. On the contrary, LOH on chromosome arms 9p
Fig. 1 – Venn diagram demonstrating the coexistence of
chromosomal alterations. The influence on tumour
recurrence was demonstrated on the colour bars – red and
blue reflect the fraction of recurrent and non-recurrent
meningiomas, respectively (For interpretation of the
references to colour in this figure legend, the reader is
referred to the web version of the article.).
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in two loci (1p33-32.3 and 22q 22q11.23) was the prognostic
factor of either tumour recurrence or a higher WHO grade.
Mutual relationships between the signiﬁcant aberrations of
particular chromosomes were veriﬁed. More than one LOH was
encountered in 73.8% (93 of 126) of patients without and 91.4%
(32 of 35) of those with MG recurrence (p = 0.53). On the other
hand, patients with subsequent MG surgery had a signiﬁcantly
greater total number of LOHs (3.9; SD  2.9) than patients
without recurrence (2.7; SD  2.8) (p = 0.02). Considering
particular chromosome arms, mutual alterations of 1p and
14q posed a greater risk of relapse (62.5%) compared to the
others (37.5%) (p < 0.01). Although frequently occurring in
MGs, the LOH on 22q or its combination with 1p or 14q were not
correlated with future tumour recurrence in our series (Fig. 1).
Since the coexistence of loss on 1p and 14q was a relapse-
speciﬁc chromosomal anomaly, these cases needed elabora-
tion. Out of all 8 patients exhibiting LOHs on 1p/14q, 3 had MG
located in the falcine/parasagittal region. We went forward
and re-evaluated all relapsed tumours of the above location
(parasagittal/falcine); 3 patients with LOH on 1p/14q exhibited
distinct features from the rest of the cases. Thereby, new MGs
were encountered distally from their original location as well
as demonstrated local malignancy or an atypical spread along
the superior sagittal sinus.
All signiﬁcant variables of single univariate comparisons
were subjected to stepwise logistic regression. Out of the
multitude of analyzed factors, only 1p/14q LOH status (p < 0.01;
OR = 10.2, 95%CI: 1.9–55.7) and WHO grade II/III (p < 0.01;
OR = 92.0, 95%CI: 19.1–443.5) were statistically signiﬁcant andwere independent prognostic factors of the tumour recurrence.
Subsequent analysis aimed to estimate the principal compo-
nent of multivariate model, therefore the ROC curves between
these two factors were compared. AUC of 1p/14q and that of the
WHO grade was 0.56 (95%CI: 0.48–0.64) and 0.79 (95%CI: 0.72–
0.85) respectively. The insigniﬁcant difference between the two
AUCs (Z-score = 3.3, p = 0.23) conﬁrmed the similar role of either
factor in the prediction of tumour recurrence (Fig. 3).
3.2. Systematic review and meta-analysis
The initial search yielded 423 records, of which 144 were valid
for eligibility evaluation (Table 1).
Cases/reports were excluded due to either reporting
recurrences only or not mentioning them at all, reporting
generalized data only or insufﬁcient data about genetics.
Merely 6 full texts (particularly those published before 2000)
were not available. 10 studies reported the percentages only
and built the aggregate data model. Whereas 21 studies
(including our large series of MGs) provided original subjects
for the Individual Patient Data (IPD) meta-analysis of. 742
individuals. The interesting features of the pooled cohort were:
slight female predominance and prevalent age between the 5th
and 7th decade of life. All features of the cohort were consistent
with the population data [24]. MGs most frequently occupied
the convexity, skull base or falcine/parasagittal region. The
detailed characteristic of the cohort is presented in Table 2.
The total recurrence rate for the entire cohort amounted to
21.4% (159 of 742). The range between authors (among case
series n ≥ 25) in terms of reported recurrences was 4.7–46.8%
(SD  12.8%). Patient age (p = 0.31), location of MG (p = 0.06) and
its complete removal (Simpson grades 1 vs. 2/3) did not
inﬂuence future recurrence. Interestingly, male sex was more
prone to experience tumour recurrence (25.6% for males; 15.0%
for females; p < 0.01). As expected, the WHO grade MG, was
positively correlated with the recurrence rate. That denoted
11.2% (51 of 454), 41.2% (56 of 136), and 58.8% (30 of 51) for WHO
1–3 grades respectively (Fig. 4).
On the subchromosomal level, the previously published
reports occasionally replicated the previously established
disease-speciﬁc bands, including 1p36, 9p, 9p21.3, 10q, 14q,
14q32.33, 22q. Therefore, we created the derivative variables
clustering any alteration in a given chromosome arm and
added new variables to the analysis. In univariate statistics,
LOH on 13 different loci correlated with the recurrence status,
of which 3 (4p, 14q11.2 and combined 1p/14q) were different
than those referring to the WHO grading. (Table 2 – electronic
supplementary materials.)
All variables signiﬁcant in the above univariate analyses
were included in the stepwise logistic regression that aimed to
identify independent recurrence-associated factors. Thereby,
parallel to the WHO grades II/III (p < 0.01, OR 90.38; 95%CI:
18.68–437.27), any alteration within chromosome 14 (p = 0.04,
OR 3.52; 95%CI: 1.02–12.13) increased the risk of MG relapse.
89.68% of cases were correctly classiﬁed to the regression
model. The comparison of ROC curves between the WHO
grading and any LOH on chromosome 14 indicated WHO grade
II or III as a prominent prognostic factor of tumour recurrence
(AUC of WHO = 0.74, 95%CI: 0.69–0.78; AUC of LOH on 14 = 0.65,
95%CI: 0.59–0.70; Z-score = 1.9 and p = 0.06 for comparison
Fig. 2 – Parasagittal/falcine meningiomas. The aggressive behaviour of benign meningiomas (MGs) attributed to concurrent
anomalies on 1p and 14q. Chromosomal alterations were shown in the table, particularly the combined LOH on 1p/14q.
Tumour progression was demonstrated in patients number 1 (A–D) and 6 (E–H). The red arrow denotes head scans after the
MG recurrence. The primary tumour location was marked with an asterisk (*) on axial planes of preoperative computer
tomography. Patient 1: C, D – axial and coronal planes, respectively, of 8-year postoperative magnetic resonance imaging
presenting recurrent MG crossing the midline, arachnoid matter and bony margins (yellow arrows). Patient 6: F, G – 1-year
follow-up scans revealed recurrent MG on both sides of superior sagittal sinus (solid line yellow arrow) and in distant falcine
location (dashed line yellow arrow). H – extremely aggressive character behaviour of the recurred MG (still WHO grade I)
presented in <2 years from the primary diagnosis. The seemingly complete tumour removal did not prevent regrowth distant
from the original location. This pattern of progression seems unusual for benign MGs; the metastasis along the falx and/or
superior sagittal sinus was strongly suspected (either venous or cerebrospinal fluid routes are probable). Abbreviation: LOH –
loss of heterozygosity. (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of the article.)
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Fig. 3 – Receiver operating characteristic (ROC) curves of
WHO grading and concurrent LOHs on chromosome arms
1p and 14q. Area under ROC curve of WHO grading was
greater than those of double LOH status, though the
difference between the areas was not statistically
significant. Abbreviations: WHO – World Health
Organization, LOH – loss of heterozygosity.
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prediction value for the tumour recurrence (sensitivity of 62.77
(95%CI: 54.1–70.9) and speciﬁcity of 79.96 (95%CI: 76.2–83.4))
than LOH on 14 status (sensitivity of 50.00 (95%CI: 26.0–74.0)
and speciﬁcity of 72.84 (95%CI: 61.8–82.1)). Particularly, 65.8%
(25 of 38) of tumours presenting with both WHO grades II/III
and any LOH on 14 recurred, compared to only 8.9% (20 of 224)
of without these features.
According the results of the IPD meta-analysis, the WHO
tumour grading should be considered together with altera-
tions within chromosome 14 while predicting the MG recur-
rence. To note, all relapse-speciﬁc genetic aberrations valid in
univariate comparisons (LOH on 4p, 14q11.2 and combined 1p/
14q) were excluded from the stepwise regression model and
remained invalid.
Out of all studies included in the quantitative synthesis, 10
of them were suitable for the Aggregated Data model of meta-
analysis. Total ORs (ﬁxed effects model) were calculated for
above loci. The highest OR was obtained for LOH on arm 14q
and therefore it is the most prominent recurrence-related
abnormality (OR = 7.59; 95%CI: 4.25–13.58). The conﬁdence
interval for LOH on 1p was narrow (OR = 5.59; 95%CI: 3.59–8.05)
which reﬂected OR estimation of higher accuracy than for 14q
anomaly. On the other hand, greater heterogeneity was
observed among studies investigating LOH on 1p (Cochrane-
Q = 11.65, p = 0.02) than 14q (Cochrane-Q = 5.15, p = 0.08).
4. Discussion
Molecular biology has become as a powerful tool that has
contributed to diagnosing tumours, the understanding the
tumorigenesis and created a promising target for futuretherapies. Despite its potential, the application of genetics
in MGs has neither been widely accepted nor incorporated into
the clinical practice [3,16]. An unexpected and rapid recurrence
of a locally aggressive tumour may occur even after the
complete removal of a benign MG (Fig. 2 Fig. 2). High WHO
grades are an undisputed yet imprecise prognostic factor in
MG recurrence [5,8]. Parallel to the WHO classiﬁcation, surgical
completeness, and high KI-67 index determine progression-
free survival [8,10]. However, due to some yet unexplored
factors the regrowth remains unpredictable in a small subset
of MGs [11,21]. Precise determination of tumour behaviour
would streamline the patient-tailored therapy by allowing
early screening for surgery vs. expectant management as well
as to modify the extent of resection. A speciﬁc genotype of
recurring MGs has been sought for years. Steudel et al. [18]
correlated cytogenetic changes with clinical ﬁndings and
proved the deleterious role of chromosome 22 anomaly on MG
recurrence. Other papers conﬁrmed the role of instability
within this chromosome, though did not replicate its impact
on relapse occurrence or progression-free survival
[11,13,14,20]. Mutation or loss of gene NF2 located on 22q is
responsible for tumorigenesis, as found in up to one half of
MGs [6,17,21]. Ketter et al. examined almost 200 patients for
cytogenetic aberrations on chromosome 22 and 1 using
Giemsa banding and demonstrated the need for recurrence-
associated cytogenetic classiﬁcation of MGs [13]. Patients with
monosomy or any loss of the short arm of one chromosome 1
had worse prognosis than others [13]. Authors created a
regimen of patient surveillance following surgery based on
both the WHO grade and structure of chromosomes 1 and 22
[13]. Studies of the deleterious role of chromosome 1 in
predicting tumour behaviour revealed that deleted regions of
arm 1p (1p34.2-ter) with multiple cancer-associated genes are
frequently found in recurred MGs [21]. Three other studies also
demonstrated strong inﬂuence of LOH on 1p on recurrence
[2,8,12]. Loss on 14q (together with 6q) was more common in
recurrent tumours [4]. Two independent studies [12,15]
postulated coexisting anomalies of 1p and 14q to increase
the probability of relapse. Pﬁsterer et al. performed multivari-
ate analysis of clinical factors related with surgery, magnetic
resonance spectroscopy, histopathology and three chromo-
somal aberrations [15]. Aggressive phenotype of sporadic MG
was involved with abnormalities within 1p and 14q. Hamilton
proved that 1p/14q co-deletion is strongly associated with
tumour recurrence, speciﬁcally relapse OR of 52.5 and 15.7 for
LOH on 1p36 and 14q11.2 respectively [12]. The analysis of our
series deﬁnitely supports the ﬁndings of the above two
authors. Identical chromosome arms, namely 1p and 14q
were identiﬁed in either uni- or multivariate analysis to
increase the incidence of relapse. The combination of LOH on
1p and 14q was an independent prognostic factor, parallel to
WHO grade II or III. As several loci were evaluated in own
series, we veriﬁed the role of total number of genetic
abnormalities in a single patient. Higher number of aberra-
tions correlated with higher recurrence rate. This result is
clearly supported by literature [4], but remains invalid when
analyzed together with the WHO grading and combined LOH
on 1p/14q. Another key ﬁnding of our series is that the relapse-
related regions were different from the alterations speciﬁc for
higher WHO grade. Domingues et al. isolated only the
Table 1 – The prevalence of the loss of heterozygosity (LOH) in selected loci.
The percentages refer to columns of either recurrent, non-recurrent, WHO I or II/III subset. Signiﬁcant comparisons are in bold. Orange colour
denotes signiﬁcant differences in LOH between the recurring and non-recurring meningiomas. Blue colour denotes that difference between
WHO I and WHO II/III grades. Abbreviations: LOH – loss of heterozygosity, WHO – World Health Organization grading system, * – denotes any loss
of heterozygosity encountered in the given chromosome arm.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 4 3 9 – 4 4 8444alteration of chromosomes 7, 14, and 18 as of predictive value
for poor outcome [11]. However, the authors emphasized that
the above individual chromosomes lost their prognostic value
once a complex karyotype (≥2 altered chromosomes) was
included in the analysis. Our results do not share that opinion
as a combination of alterations on 1p and 14q retained the
genetic model of recurrence. Domingues noted that del(1p36)
and monosomy 14 coexisted in several relapsing tumours in
her series, which can explain these discrepancies [11].Our prospective study has substantial drawbacks. Despite
the scrupulous specimen collection for several years and 27
examined loci, our series was limited to only TWO neurosur-
gical centres, time-to-recurrence was not tracked, either CT or
MRI was used and timing of imaging for recurrence was not
established. Of concern, not every sample was informative for
all examined loci, thus the results were obtained for valid data.
Various loci were examined, pathologists utilized inconsistent
3rd or 4th editions of the WHO classiﬁcation, and unselected
Fig. 4 – Recurrence rates and percentages of meaningful chromosomal alterations for specific tumour locations. Cranial base
meningiomas recurred less frequently and had less abnormalities within chromosomes 1 and 14. Abbreviations: WHO –
World Health Organization, LOH – loss of heterozygosity.
Table 2 – Patient characteristics – single cohort pooled for the individual patient data meta-analysis.
Feature Mean (SD; min–max) Data completeness
(%)
Comparison to population
of meningiomas (n  17k) [1]
Age [years] 55.3 (14.6; 10–101) 68.9 57.4 (1–96)
( p < 0.01)
Fraction
[% of complete observations]
Sex 69.7 69.7% females ( p < 0.01)
Females 59.2
Males 40.8










GTR 78.3 22.4* NS




Abbreviations: SD – standard deviation, GTR – gross total resection, * – insufﬁcient data completeness, NS – not stated, k – kilo (103).
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Fig. 5 – Receiver operating characteristic (ROC) curves of WHO grades II/III and LOH on chromosome arms 14. B–C. Forest plots
of Aggregate Data model of meta-analysis of chromosomal aberrations. Relevant odds ratios (OR) were provided with their
95% confidence intervals (95%CI). B. Aggregate OR (fixed effects model) for loss of heterozygosity (LOH) on 1p, 14q and 22.
Note that total OR for LOH on 14q represent the highest value.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 4 3 9 – 4 4 8446locations entailed different resection rates. In LOH studies, it is
difﬁcult to distinguish between losses of one allele or gains of
the other when there could be contaminations due to non-
tumoral cells from the stroma. Furthermore, clinical and
demographic data (including Simpson grade, detailed location,
age, sex and occasionally even the WHO grade) were sparsely
reported. Although the authors of previous papers provided
either raw or summarized patient data, all were included. We
aimed to not miss relevant data in synthesizing and therefore
utilized both methodologies (IPD and Aggregate Data).
Following Domingues et al. [11], we presented the second
largest series evaluating a broad array of regions for their
putative prognostic value.
Encouraged by the obtained prognostic value of 1p/14q
alterations, we discovered a certain characteristic. The
parasagittal and falcine locations were selected for two
reasons: because we noticed that in the pooled cohort the
recurrence rate was the highest in those locations and also
because 3 of 8 cases with the 1p/14q alteration were
parasagittal/falcine MGs. We intended to demonstrate an
unusual recurrence pattern in two of our cases (Fig. 2) ofparasagittal MGs with the 1p/14q alteration. Detailed analysis
of patients with recurring MGs of parasagittal and falx
locations revealed that combined chromosomal alteration
on 1p and 14q entail rapid progression. Aggressive behaviour is
demonstrated by the regrowth of MG separated from its
primary origin. The progression pattern of recurrent MGs
mimicked drop metastases within cerebrospinal ﬂuid as in
other neuroepithelial brain tumours, but were limited to a
single location. One study described an aggressive phenotype
of MG and attributed its occurrence to loss of 1p and 14q, but is
limited to a small series [25].
The authors of relevant reviews on MGs simply lumped
together the previous ﬁndings and listed recurrence-speciﬁc
loci: 1p, 9p, 10q, 14q, 14p and 22 and regarded them as
recurrence-speciﬁc abnormalities [3,7,10,17,26]. Lee et al. ﬁrst
utilized the Gene Expression Omnibus database to stipulate a
speciﬁc genetic proﬁle of recurrent MGs in a combination of
own series and pooled cohort [4]. Since chromosomal aberra-
tions have not been pooled yet, it is vital to examine all
accessible factors at karyotype level in a full systematic review
fashion. The Cochrane Collaboration recommends pooling
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 4 3 9 – 4 4 8 447case series in rare disease research, such as our meta-analysis
[27]. By means of both analytical approaches, the WHO
classiﬁcation (particularly grade II and III) and any alteration
on chromosome 14p and 1p characterized the recurrence
trend in MGs. Confronting the clinical data with cytogenetic
ﬁndings yield MG-speciﬁc pattern of recurrence. Until proven
otherwise, these variables (WHO, LOH on 1p, 14q and 14) CAN
BE regarded as independent factors of tumour aggressive
behaviour. Multivariate analysis rejected speciﬁc loci and
otherwise included summarized variables such as any loss on
arms 1p or 14q. Moreover, pooled cohorts carry a risk of
publication bias, including the authors' individual prefer-
ences in selecting published series, buried negative results,
different candidate genes assessed using different laboratory
methods (FISH, microsatellite, and CGH), the reviewers'
rejections of noteworthy manuscripts or simply the language
barrier [28].
Beyond the chromosomal level, alternative genetic path-
ways should be included in the interpretation of progression in
some MGs [2,4,11]. To date, we have merely touched the tip of
the iceberg in recognizing a pattern of tumour progression and
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